Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Thomas Smith maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $28 to $22.
Leerink Partners analyst Thomas Smith maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $28 to $22.